Pulmonary arterial hypertension (PAH) is a complex disease characterized
by inappropriate scarring of the pulmonary vasculature
which results in increased vascular resistance,
elevated pulmonary artery pressure and eventually
right heart dysfunction. While the diagnostic evaluation
of patients is complex, numerous proven therapies
are now available. At Newark Beth Israel, the same
multidisciplinary approach to evaluation for lung transplant is applied
to patients with PAH.
A unique feature of the program
is the integrated . In this setting, patients receive sophisticated
evaluation and treatment of pulmonary hypertension
associated with parenchymal lung disease. Evaluation
in this program provides access to the Newark Beth
Israel Lung and Heart/Lung Transplant Programs.
[ top ]
|
